These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

328 related articles for article (PubMed ID: 33798735)

  • 41. Microtubule-Associated Protein Tau, α-Tubulin and βIII-Tubulin Expression in Breast Cancer.
    Im S; Yoo C; Jung JH; Jeon YW; Suh YJ; Lee YS; Choi HJ
    Korean J Pathol; 2013 Dec; 47(6):534-40. PubMed ID: 24421846
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Overexpression of class III beta-tubulin predicts good response to taxane-based chemotherapy in ovarian clear cell adenocarcinoma.
    Aoki D; Oda Y; Hattori S; Taguchi K; Ohishi Y; Basaki Y; Oie S; Suzuki N; Kono S; Tsuneyoshi M; Ono M; Yanagawa T; Kuwano M
    Clin Cancer Res; 2009 Feb; 15(4):1473-80. PubMed ID: 19228748
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Is taxane/platinum/5 fluorouracil superior to taxane/platinum alone and does docetaxel trump paclitaxel in induction therapy for locally advanced oral cavity cancers?
    Noronha V; Patil V; Joshi A; Muddu V; Bhattacharjee A; Juvekar S; Arya S; Chaturvedi P; Chaukar D; Pai PS; Dcruz AK; Prabhash K
    Indian J Cancer; 2015; 52(1):70-3. PubMed ID: 26837979
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Multiple mechanisms underlying acquired resistance to taxanes in selected docetaxel-resistant MCF-7 breast cancer cells.
    Wang H; Vo T; Hajar A; Li S; Chen X; Parissenti AM; Brindley DN; Wang Z
    BMC Cancer; 2014 Jan; 14():37. PubMed ID: 24447372
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The activity of taxanes compared with bleomycin, etoposide, and cisplatin in the treatment of sex cord-stromal ovarian tumors.
    Brown J; Shvartsman HS; Deavers MT; Ramondetta LM; Burke TW; Munsell MF; Gershenson DM
    Gynecol Oncol; 2005 May; 97(2):489-96. PubMed ID: 15863149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    Lemstrova R; Melichar B; Mohelnikova-Duchonova B
    Cancer Chemother Pharmacol; 2016 Dec; 78(6):1101-1111. PubMed ID: 27250969
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Low Intensity Ultrasound as an Antidote to Taxane/Paclitaxel-induced Cytotoxicity.
    Amaya C; Smith ER; Xu XX
    J Cancer; 2022; 13(7):2362-2373. PubMed ID: 35517405
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Taxanes in combined modality therapy for solid tumors.
    Choy H
    Crit Rev Oncol Hematol; 2001 Mar; 37(3):237-47. PubMed ID: 11248579
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Taxane-based Combination Therapies for Metastatic Prostate Cancer.
    Corn PG; Agarwal N; Araujo JC; Sonpavde G
    Eur Urol Focus; 2019 May; 5(3):369-380. PubMed ID: 29275145
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Retrospective analysis of second-line chemotherapy outcomes with paclitaxel or docetaxel in correlation with STMN1 polymorphism in advanced non-small cell lung cancer patients.
    Powrózek T; Mlak R; Krawczyk P; Bartoń S; Biernacka B; Małecka-Massalska T; Milanowski J
    Clin Transl Oncol; 2016 Jan; 18(1):33-9. PubMed ID: 26148901
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical efficacy and safety of Aidi injection plus paclitaxel-based chemotherapy for advanced non-small cell lung cancer: A meta-analysis of 31 randomized controlled trials following the PRISMA guidelines.
    Xiao Z; Wang C; Zhou M; Hu S; Jiang Y; Huang X; Li N; Feng J; Tang F; Chen X; Ding J; Chen L; Wang Y; Li X
    J Ethnopharmacol; 2019 Jan; 228():110-122. PubMed ID: 30243827
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Chemoresistance in non-small cell lung cancer.
    Sève P; Dumontet C
    Curr Med Chem Anticancer Agents; 2005 Jan; 5(1):73-88. PubMed ID: 15720263
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of paclitaxel, docetaxel, gemcitabine and vinorelbine in non-small-cell lung cancer.
    Clegg A; Scott DA; Sidhu M; Hewitson P; Waugh N
    Health Technol Assess; 2001; 5(32):1-195. PubMed ID: 12065068
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Resistance to first line platinum paclitaxel chemotherapy in serous epithelial ovarian cancer: the prediction value of ERCC1 and Tau expression.
    Steffensen KD; Smoter M; Waldstrøm M; Grala B; Bodnar L; Stec R; Szczylik C; Jakobsen A
    Int J Oncol; 2014 May; 44(5):1736-44. PubMed ID: 24585004
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Tangeretin, a citrus pentamethoxyflavone, antagonizes ABCB1-mediated multidrug resistance by inhibiting its transport function.
    Feng SL; Yuan ZW; Yao XJ; Ma WZ; Liu L; Liu ZQ; Xie Y
    Pharmacol Res; 2016 Aug; 110():193-204. PubMed ID: 27058921
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Activation of ALDH1A1 in MDA-MB-468 breast cancer cells that over-express CYP2J2 protects against paclitaxel-dependent cell death mediated by reactive oxygen species.
    Allison SE; Chen Y; Petrovic N; Zhang J; Bourget K; Mackenzie PI; Murray M
    Biochem Pharmacol; 2017 Nov; 143():79-89. PubMed ID: 28756208
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Microtubule-associated parameters as predictive markers of docetaxel activity in advanced breast cancer patients: results of a pilot study.
    Bernard-Marty C; Treilleux I; Dumontet C; Cardoso F; Fellous A; Gancberg D; Bissery MC; Paesmans M; Larsimont D; Piccart MJ; Di Leo A
    Clin Breast Cancer; 2002 Dec; 3(5):341-5. PubMed ID: 12533264
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Paclitaxel (Taxol) and docetaxel (Taxotere): results of phase II trials in monochemotherapy].
    Fumoleau P; Perrocheau G; Maugard-Louboutin C; Lemevel B
    Bull Cancer; 1995 Aug; 82(8):629-36. PubMed ID: 7492819
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Live Imaging to Study Microtubule Dynamic Instability in Taxane-resistant Breast Cancers.
    Wang R; Wang H; Wang Z
    J Vis Exp; 2017 Feb; (120):. PubMed ID: 28287508
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Targeting prolyl isomerase Pin1 as a promising strategy to overcome resistance to cancer therapies.
    Wu W; Xue X; Chen Y; Zheng N; Wang J
    Pharmacol Res; 2022 Oct; 184():106456. PubMed ID: 36116709
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.